The Chemours Company experienced a slight 2% decrease in net sales to $1.3 billion in Q4 2025 compared to the prior year, primarily due to a 4% decrease in volume. Despite this, the Thermal & Specialized Solutions (TSS) segment achieved record fourth-quarter growth of 37% in Opteon™ Refrigerants. The company reported a net loss of $47 million, or $0.31 per diluted share, a significant increase from the $11 million net loss in Q4 2024, mainly due to lower cost absorption, an unfavorable product mix in APM, and higher income tax provisions. Adjusted EBITDA for the quarter was $128 million, down 24% year-over-year.

The Chemours Company delivered a strong second quarter in 2025, with net sales increasing by 4% year-over-year to $1.615 billion and Adjusted EBITDA rising by 22% to $253 million. This performance was primarily fueled by robust volume growth in Thermal & Specialized Solutions, particularly for Opteon™ Refrigerants, and strong pricing in Advanced Performance Materials. Despite a net loss of $381 million due to litigation-related charges, the company's operational results exceeded expectations, and it made significant progress on environmental settlements.

The Chemours Company reported net sales of $1.4 billion in the first quarter of 2025, in line with the prior-year quarter. The company experienced a net loss of $4 million, or $0.03 per diluted share, compared to net income of $54 million in the prior-year quarter. Adjusted EBITDA decreased by 13% year-over-year.

Chemours saw a 1% YoY revenue decline in Q4 2024, impacted by lower pricing. However, Adjusted EBITDA grew by 2%, supported by cost efficiencies in Titanium Technologies and volume growth in Thermal & Specialized Solutions. Net loss improved to $8 million from $18 million in Q4 2023.

Chemours reported third quarter 2024 results with net sales of $1.5 billion, in line with the prior-year quarter. Net loss attributable to Chemours was $27 million, or $0.18 per diluted share. Adjusted net income was $61 million, or $0.40 per diluted share. Adjusted EBITDA was $208 million. The company also outlined a refreshed corporate strategy focused on sustainable growth and long-term value creation.

Chemours reported Q2 2024 financial results with net sales of $1.5 billion, a 6% decrease year-over-year. Net income attributable to Chemours was $70 million, or $0.46 per diluted share, compared to a net loss of $376 million in the prior-year quarter. Adjusted EBITDA was $206 million, down from $324 million in the corresponding prior-year quarter.

Chemours reported Q1 2024 results with net sales of $1.4 billion, a 12% decrease year-over-year. Net income attributable to Chemours was $52 million, or $0.34 per diluted share, compared to $145 million in the prior-year quarter. Adjusted EBITDA was $193 million, down from $304 million in the corresponding prior-year quarter.

Chemours reported Q4 2023 net sales of $1.4 billion, a 2% increase year-over-year. The company experienced a net loss of $18 million, or a loss of $0.12 per diluted share. Adjusted EBITDA improved 47% year-over-year to $176 million, driven by favorable demand in TSS and lower input costs.

Chemours reported Q3 2023 results with net sales of $1.5 billion, a net income of $20 million (EPS of $0.13), and an adjusted EBITDA of $247 million. The company launched the TT Transformation Plan to drive approximately $100 million in run-rate cost savings starting in 2024 and completed the sale of the Glycolic Acid business for $138 million. Due to a weaker demand outlook, the full-year adjusted EBITDA guidance was lowered by 8% at the midpoint.

Chemours' second quarter 2023 results showed net sales of $1.6 billion, a net loss of $(376) million, and adjusted EBITDA of $324 million. The company announced the closure of its Kuan Yin, Taiwan titanium dioxide manufacturing facility and reached a comprehensive settlement of PFAS-related drinking water claims. Due to weaker second-half demand visibility, the full-year Adjusted EBITDA guidance was lowered by 9% at the midpoint.

Chemours reported Net Sales of $1.5 billion, Net Income of $145 million, and Adjusted EBITDA of $304 million for Q1 2023. The company experienced strong performance in its Thermal & Specialized Solutions (TSS) segment, driven by demand for OpteonTM solutions, while the Titanium Technologies (TT) segment faced challenges due to lower demand.

Chemours' Q4 2022 results reflect a challenging quarter with net sales down 15% year-over-year and a net loss of $(97) million. Adjusted EBITDA decreased by 61% to $120 million. Despite the weak quarter, the company highlighted record annual results in TSS and APM segments.

Chemours reported a 6% year-over-year increase in net sales to $1.8 billion for Q3 2022. Net income was $240 million, resulting in an EPS of $1.52. Adjusted EBITDA decreased by 2% year-over-year to $363 million. The APM and TSS segments delivered strong results, while the Titanium Technologies segment faced headwinds.

Chemours reported record net sales of $1.9 billion, up 16% year-over-year, driven by strong demand across all segments. Record Adjusted EBITDA for both TSS and APM. The company is now targeting the high end of Adjusted EBITDA guidance and increasing Free Cash Flow outlook.

Chemours reported a strong first quarter with net sales of $1.8 billion, up 23% year-over-year. The company's TSS and APM segments delivered exceptional results, reflecting strong pricing and demand. As a result, Chemours raised its full-year Adjusted EBITDA guidance by 12% at the midpoint.

Chemours reported a strong fourth quarter with net sales of $1.6 billion, up 18% year-over-year, and adjusted EBITDA of $307 million, up 25% year-over-year. The company's performance was driven by higher pricing and strong demand across its segments, particularly in Titanium Technologies and Advanced Performance Materials.

Chemours reported strong Q3 2021 results with net sales of $1.7 billion, a 36% increase year-over-year. Net income and Adjusted Net Income were both $214 million, with EPS and Adjusted EPS of $1.27. Adjusted EBITDA reached $372 million, up 77% year-over-year, resulting in Free Cash Flow of $244 million. The company has raised its full-year 2021 outlook for Adjusted EBITDA and Adjusted EPS and expects Free Cash Flow greater than $500 million.

Chemours reported a strong second quarter in 2021, with net sales of $1.7 billion, a 51% increase year-over-year. Net income was $66 million, with an EPS of $0.39. Adjusted EBITDA was $366 million, up 120% year-over-year, and free cash flow was $189 million, an increase of $139 million year-over-year.

Chemours reported strong first quarter results with net sales of $1.4 billion, a 10% increase year-over-year. The company raised its full-year Adjusted EBITDA guidance by $100 million and now expects Free Cash Flow to be greater than $450 million.

Chemours Company reported fourth-quarter net sales of $1.3 billion, nearly level with the prior-year quarter. Net income was $19 million, resulting in EPS of $0.11. Adjusted EBITDA increased by 8% year-over-year to $246 million, driven by higher volume, lower costs, and favorable currency impact.

Chemours reported net sales of $1.2 billion and net income of $76 million for the third quarter of 2020. The company's adjusted EBITDA was $210 million, and it generated a free cash flow of $252 million. The results reflect the company's resilience and execution in a challenging environment.

Chemours reported net sales of $1.1 billion and net income of $24 million, with an EPS of $0.15. Adjusted EPS was $0.18. The company's free cash flow was $50 million, a $167 million improvement from the prior year. The results were impacted by lower volumes across all segments due to COVID-19.

Chemours reported Q1 2020 net sales of $1.3 billion and net income of $100 million, or $0.61 per diluted share. Adjusted Net Income was $118 million, with Adjusted EPS of $0.71. The company enacted measures to protect employees and reduce costs by $160 million, while also reducing FY 2020 CAPEX by $125 million. Due to demand uncertainty, the company withdrew its FY 2020 guidance.

Chemours reported Q4 2019 net sales of $1.4 billion and a net loss of $(317) million, or $(1.94) per diluted share. Adjusted net income was $92 million, or $0.56 per diluted share, and adjusted EBITDA was $227 million. The company finished the year strong with $304 million in free cash flow.